Iovance Biotherapeutics: Buy the Dip? [The Motley Fool]
Iovance Biotherapeutics, Inc. (IOVA)
Last iovance biotherapeutics, inc. earnings: 2/25 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
iovance.com
Company Research
Source: The Motley Fool
Iovance Biotherapeutics: Buy the Dip? The company is flush with cash and wields a promising therapeutic pipeline. Is its recent tumble a buying opportunity? Cellular medicines have finally begun to demonstrate their potential in the real world after decades of promise in the lab. The U.S. Food and Drug Administration (FDA) approved the first such drug, the chimeric antigen receptor T-cell (CAR-T) drug Kymriah, in summer 2017, followed by the CAR-T drug Yescarta two months later. Both drugs take aim at blood cancers, but that's just scratching the surface of what cellular medicines can likely do. Companies are now developing a variety of cellular medicines based on various immune cells as potential treatments for blood cancers and solid tumors, inflammatory diseases, and more. Such immunotherapy drug candidates include CRISPR-engineered T cells, "off-the-shelf" natural killer (NK) cells , and tumor-infiltrating lymphocytes (TIL). The latter opportunity is being pursued most notably by
Show less
Read more
Impact Snapshot
Event Time:
IOVA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IOVA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IOVA alerts
High impacting Iovance Biotherapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
IOVA
News
- Is Iovance Biotherapeutics Stock a Buy Now? [Yahoo! Finance]Yahoo! Finance
- Market Sentiment Around Loss-Making Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) [Yahoo! Finance]Yahoo! Finance
- Iovance Biotherapeutics: Riding The Favorable Moment Could Bring Excellent Results [Seeking Alpha]Seeking Alpha
- Iovance (IOVA) Stock Surges More Than 60% YTD: Here's Why [Yahoo! Finance]Yahoo! Finance
- Better Growth Biotech Buy: Iovance Biotherapeutics vs CRISPR Therapeutics [Yahoo! Finance]Yahoo! Finance
IOVA
Earnings
- 2/28/24 - Miss
IOVA
Sec Filings
- 4/17/24 - Form 4
- 4/17/24 - Form 4
- 4/17/24 - Form 4
- IOVA's page on the SEC website